Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05148559
Other study ID # MCL10517
Secondary ID U01IP001093
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 12, 2021
Est. completion date December 2023

Study information

Verified date April 2023
Source Marshfield Clinic Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vaccine uptake in the United States is lower in rural areas, especially for HPV vaccine. Reminder/recall has been identified as an effective strategy to increase vaccination rates. This study will assess the impact by rurality of vaccine reminder notices sent via the parent's preferred method of communication on HPV vaccination among 12 year-old patients in a regional healthcare system.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 5451
Est. completion date December 2023
Est. primary completion date November 2, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Years to 12 Years
Eligibility Inclusion Criteria: - Marshfield Clinic Health System patient aged 12 years with at least one preventive visit or two evaluation & management visits with a Marshfield Clinic Health System provider in the last 36 months - Due for at least one adolescent vaccine (HPV, MenACWY, Tdap) Exclusion Criteria: - Primary care provider is not affiliated with Marshfield Clinic Health System - Opted out of Marshfield Clinic Health System vaccine reminder notifications - Missing or invalid contact information - Deceased

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reminder Sent Via Preferred Method of Communication
Parents of 12 year-old patients due for =1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
Reminder Sent Via Mailed Letter
Parents of 12 year-old patients due for =1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.

Locations

Country Name City State
United States Marshfield Clinic Health System Marshfield Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
Huong McLean, PhD Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients that received 1 dose of HPV vaccine during follow-up based on electronic health data Receipt of 1 dose of HPV vaccine within 90 days of receipt of reminder (yes/no) will be assessed using vaccination data available from the Marshfield Clinic Health System electronic health record, which includes vaccinations administered outside of MCHS through data exchanges with the Wisconsin Immunization Registry. Specifically patients will be classified as having received 1 dose of HPV vaccine if they have record of receipt of HPV vaccine with a vaccination date during the 90-day follow-up period. 90 days
See also
  Status Clinical Trial Phase
Completed NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine Phase 2
Completed NCT00250276 - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase 3
Completed NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase 4
Recruiting NCT05266898 - Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Phase 4
Completed NCT03763565 - Effectiveness of HPV Vaccine in Thai Adult Women
Completed NCT00877877 - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. Phase 3
Completed NCT00811798 - Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. Phase 3
Recruiting NCT05884697 - Let's K-Talk - HPV Study for Ethnic Koreans N/A
Completed NCT00637195 - Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) Phase 3
Completed NCT00798265 - A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Phase 1
Completed NCT00423046 - Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Phase 3
Completed NCT00294047 - Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Phase 3
Recruiting NCT04469569 - Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors N/A
Not yet recruiting NCT04671823 - Changes in the Prevalence of Oncogenic HPV Types
Recruiting NCT03350698 - Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Phase 4
Completed NCT02370459 - AFIX to Improve HPV Vaccination N/A
Completed NCT00456807 - Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Phase 3
Completed NCT03501992 - Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination N/A